JP2023502941A5 - - Google Patents

Info

Publication number
JP2023502941A5
JP2023502941A5 JP2022528029A JP2022528029A JP2023502941A5 JP 2023502941 A5 JP2023502941 A5 JP 2023502941A5 JP 2022528029 A JP2022528029 A JP 2022528029A JP 2022528029 A JP2022528029 A JP 2022528029A JP 2023502941 A5 JP2023502941 A5 JP 2023502941A5
Authority
JP
Japan
Prior art keywords
formulation
solid
years
age
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502941A (ja
Filing date
Publication date
Priority claimed from US16/867,514 external-priority patent/US10945992B1/en
Application filed filed Critical
Publication of JP2023502941A publication Critical patent/JP2023502941A/ja
Publication of JP2023502941A5 publication Critical patent/JP2023502941A5/ja
Pending legal-status Critical Current

Links

JP2022528029A 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法 Pending JP2023502941A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US62/934,898 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US63/018,136 2020-04-30
US16/867,514 2020-05-05
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (2)

Publication Number Publication Date
JP2023502941A JP2023502941A (ja) 2023-01-26
JP2023502941A5 true JP2023502941A5 (cg-RX-API-DMAC10.html) 2023-11-21

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528029A Pending JP2023502941A (ja) 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法

Country Status (9)

Country Link
US (5) US10945992B1 (cg-RX-API-DMAC10.html)
EP (1) EP4058012A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023502941A (cg-RX-API-DMAC10.html)
KR (1) KR20220123224A (cg-RX-API-DMAC10.html)
CN (1) CN115605197A (cg-RX-API-DMAC10.html)
CA (1) CA3155900A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022005813A (cg-RX-API-DMAC10.html)
TW (1) TW202128144A (cg-RX-API-DMAC10.html)
WO (1) WO2021097038A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210124188A (ko) * 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21042A (en) 1858-07-27 yerby
US21647A (en) 1858-10-05 Construction of animal-traps
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU3004997A (en) 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases
WO2005016906A1 (en) 2003-08-14 2005-02-24 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
TR200301552A1 (tr) 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US9763912B2 (en) * 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2024069192A5 (cg-RX-API-DMAC10.html)
JP2016518387A5 (cg-RX-API-DMAC10.html)
JP6353577B2 (ja) 組み合わせ組成物
UA58576C2 (uk) Фармацевтична композиція, що містить целекоксиб
JP2005508840A5 (cg-RX-API-DMAC10.html)
JP2021525729A5 (cg-RX-API-DMAC10.html)
PT92949B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cisteina para o tratamento de doencas associadas com infeccoes provocadas por virus da imunodeficiencia humano
JP2021525746A5 (cg-RX-API-DMAC10.html)
JP2018507243A5 (cg-RX-API-DMAC10.html)
JP2022550919A5 (cg-RX-API-DMAC10.html)
JP2018502168A5 (cg-RX-API-DMAC10.html)
JP2002528502A5 (cg-RX-API-DMAC10.html)
JP2024533756A5 (cg-RX-API-DMAC10.html)
JP2024527023A5 (cg-RX-API-DMAC10.html)
BRPI0107493B1 (pt) Substâncias para uso no tratamento de psoríase
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
JP2018529766A5 (cg-RX-API-DMAC10.html)
JP2020519576A5 (cg-RX-API-DMAC10.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
Linfert et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future
JP2025159244A (ja) 低亜鉛血症治療剤
JP2018529747A5 (cg-RX-API-DMAC10.html)
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP2022504435A5 (cg-RX-API-DMAC10.html)
SE0102887D0 (sv) New formulation